SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert Perissi who wrote (637)10/14/1996 3:50:00 AM
From: WWS   of 4342
 
Robert, I'm up late too. I'd heard the Oxford story too. If I recall, though, the "nontraditional medicine" option was going to cost subscribers about 3 - 5% MORE than the traditional option. But the story does demonstrate the growing interest in alternative healing, and even willingness of some providers (I think Oxford has 1.5 million subscribers) to pay for such treatments. However, I don't think that PRLN's research strategy with PN355 (P.S. I haven't forgotten that you discovered the name of the Chinese herb on which it is based) will persuade the medical establishment. At least it won't if PRLN stays with its strategy to take research only to the point at which they can produce a nutritional supplement instead of going all the way to a "New Drug Application". After all, they're aiming for a nutritional product (probably PN355) as early as March of next year, whereas an NDA would still be four years into the future. But their strategy might work in spite of lack of support of medical establishment, that is if they can produce dramatic early results of safety and effectiveness. But March is still a very ambitious time schedule for such a small company with so much still to be done--like how does this product interact with all the multitude of other drugs that AIDs patients could possibly be taking. Not a trivial task. Bill
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News